Close menu




January 15th, 2020 | 07:42 CET

Fresenius Peer: Will the analysts' favorite M1 Kliniken 2020 take off?

  • Medical
Photo credits: pixabay.com

Besides Fresenius, M1 Klinken AG is one of the few listed clinic operators in Germany. Unlike the clinic group, M1 has specialised in a lucrative niche: the beauty market. More and more people are helping with beauty and are generating billions in sales in the industry. In just a few years, M1 has become the market leader for beauty medicine in Germany. A growth rate of 30% is also targeted for the future. Foreign business is increasingly becoming the growth driver. After a continuous price increase between 2016 and 2018, the share has consolidated in 2019. But operationally things are still running smoothly. Analysts see more than 50% upside potential.

time to read: 1 minutes | Author: Mario Hose
ISIN: DE000A0STSQ8 , DE0005785604

Table of contents:


    All analysts convinced of growth course

    All analysts - including Commerzbank and Bankhaus Metzler - are convinced that M1 Kliniken will continue to grow at double-digit rates in the coming years and recommend the share as a buy. Five analysts expect M1 Kliniken to break through the EUR 100 million revenue barrier this year (2018: EUR 65 million). The average expectation for net income in 2020 is EUR 9.8 million (2018: EUR 6.6 million).

    Sales and profit growth foreseeable

    M1 has already laid the foundation for further revenue and profit growth in the current year. In 2019, 12 new specialist centres were opened, significantly more than in previous years (average 6 p.a.). This means that the Group now operates 36 outpatient centres for aesthetic medicine. With Dortmund, Bielefeld, Rostock, Stuttgart II and Frankfurt (M1 Dental), M1 has increased the number of locations in Germany by 5 to 28.

    In addition, larger premises were moved into Hamburg and Hanover. At the same time, M1 is specifically increasing the range of treatments offered in the existing specialist centres. For example, aesthetic laser treatments, such as hair removal, are now offered at 20 beauty locations under the "M1 Laser" brand.

    Internationalization as growth driver

    International expansion was added as an additional growth driver last year. After the first international "M1 Med Beauty" specialist centre for aesthetic medicine was opened in Vienna in December 2018, 7 foreign locations have been added in recent months. In addition to a further location in Austria (Linz), the company has successfully entered the markets in the Netherlands (Amsterdam, Rotterdam), Switzerland (Zurich) and Australia (Melbourne, Sydney, Brisbane).

    Project pipeline gives reason to expect dynamic start to 2020

    In addition, the project development for 10 further specialist centres - 5 of them in Great Britain alone - has been largely completed. The M1 Group is thus fully on track to achieve its goal: 50 specialist beauty centres by the end of 2020. M1 has already secured the necessary financing in September 2018 through a capital increase.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on December 9th, 2020 | 14:16 CET

    Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

    • Medical

    The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.

    Read

    Commented by Mario Hose on May 5th, 2020 | 08:33 CEST

    Evotec, Medigene, Memphasys - the right investment timing

    • Medical

    The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.

    Read

    Commented by Mario Hose on April 24th, 2020 | 07:36 CEST

    BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

    • Medical

    There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.

    Read